Community Research and Development Information Service - CORDIS

Abstract

1426 patients with Bechterew's disease, who had formerly (up to 30 years ago) been treated with 224-Ra were included in an epidemiological study. Among the 363 mortalities recorded, 3 were due to tumours in the skeletal region, of these 2 were observed in the haemopoietic system. On the other hand: in a group of patients, treated with higher doses, studied by Spiess, only 1 out of 55 tumours was of the haemopoietic system; a high incidence of such tumours was found among Hiroshima victims. In an effort carefully to reconsider the drug 224-Ra, two study groups of 200 patients in all were investigated 5-20 years after an injection therapy for clinical and radiological symptoms. The results: main benefit of the drug: its analgesic efficacy; apparently no decisive influence on the course of the disease; no radiation induced malignomas or other radiation damage was detected. In comparison with chemical agents used in the treatment of a.sp.: 224-Ra is very useful in cases of absolute indication.

Additional information

Authors: SCHMITT E, GESELLSCHAFT FUER STRAHLEN- UND UMWELTFORSCHUNG MBH NEUHERBERG (GERMANY);WICK R R GESELLSCHAFT FUER STRAHLEN- UND UMWELTFORSCHUNG MBH NEUHERBERG (GERMANY), GESELLSCHAFT FUER STRAHLEN- UND UMWELTFORSCHUNG MBH NEUHERBERG (GERMANY)
Bibliographic Reference: THERAPIEWOCHE, VOL. 33 (1983), PP. 3753-3755
Follow us on: RSS Facebook Twitter YouTube Managed by the EU Publications Office Top